A modified conjugated diene-based polymer and a rubber composition including a modified conjugated diene-based polymer are disclosed herein. In some embodiments, a modified conjugated diene-based polymer includes a functional group derived from a modification initiator at one terminal and a functional group derived from a modifier represented by the Formula 2 or Formula 3 at the other terminal, wherein the modified conjugated diene-based polymer having a unimodal molecular weight distribution, and a polydispersity index of 1.0 to less than 1.7. The modified conjugated diene-based polymer prepared by continuous polymerization and having remarkable processability, narrow molecular weight distribution and excellent physical properties.

A modified conjugated diene-based polymer and a rubber composition including a modified conjugated diene-based polymer are disclosed herein. In some embodiments, a modified conjugated diene-based polymer includes a functional group derived from a modification initiator at one terminal and a functional group derived from a modifier represented by the Formula 2 or Formula 3 at the other terminal, wherein the modified conjugated diene-based polymer having a unimodal molecular weight distribution, and a polydispersity index of 1.0 to less than 1.7. The modified conjugated diene-based polymer prepared by continuous polymerization and having remarkable processability, narrow molecular weight distribution and excellent physical properties.

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.

A process for preparing compounds of formula (I), or a salt or solvate thereof, including Brexpiprazole, which process comprises cyclization of a compound of formula (II) or (III), or a salt or solvate thereof. The invention also refers to intermediates of said process.

##STR00001##

A process for preparing compounds of formula (I), or a salt or solvate thereof, including Brexpiprazole, which process comprises cyclization of a compound of formula (II) or (III), or a salt or solvate thereof. The invention also refers to intermediates of said process.

##STR00001##

A process for preparing compounds of formula (I), or a salt or solvate thereof, including Brexpiprazole, which process comprises cyclization of a compound of formula (II) or (III), or a salt or solvate thereof. The invention also refers to intermediates of said process. ##STR00001##

A process for preparing compounds of formula (I), or a salt or solvate thereof, including Brexpiprazole, which process comprises cyclization of a compound of formula (II) or (III), or a salt or solvate thereof. The invention also refers to intermediates of said process. ##STR00001##

Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4 (RTN4).